Anang A. Shelat

Anang A. Shelat

Auto-generated profile, based on publicly available information

Anang A. Shelat

Department of Chemical Biology & Therapeutics MS 1000 St. Jude Children's Research Hospital Memphis TN USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2010 in Nature
Verified
Journal Article
Open access
PDF file
WGW. Armand Guiguemde
W. Armand Guiguemde
ASAnang A. Shelat
Anang A. Shelat
DBDavid Bouck
David Bouck
SDSandra Duffy
Sandra Duffy
GCGregory J. Crowther
Gregory J. Crowther
RGR. Kiplin Guy
R. Kiplin Guy
Malaria caused by Plasmodium falciparum is a disease that is responsible for 880,000 deaths per year worldwide. Vaccine development has proved difficult and resistance has emerged for most antimalarial drugs. To discover new antimalarial chemotypes, we have used a phenotypic forward chemical genetic approach to assay 309,474 chemicals. Here we disclose structures and biological activity of the entire library—many of which showed potent in vitro activity against drug-resistant P. falciparum strains—and detailed profiling of 172 representative candidates. A reverse chemical genetic study identified 19 new inhibitors of 4 validated drug targets and 15 novel binders among 61 malarial proteins. Phylochemogenetic profiling in several organisms revealed similarities between Toxoplasma gondii and mammalian cell lines and dissimilarities between P. falciparum and related protozoans. One exemplar compound displayed efficacy in a murine model. Our findings provide the scientific community with new starting points for malaria drug discovery.

30 August 2017 in Nature
Verified
Journal Article
Open access
PDF file
ESElizabeth Stewart
Elizabeth Stewart
SFSara M. Federico
Sara M. Federico
XCXiang Chen
Xiang Chen
ASAnang A. Shelat
Anang A. Shelat
CBCori Bradley
Cori Bradley
MDMichael A. Dyer
Michael A. Dyer
A protocol producing orthotopic patient-derived xenografts at diagnosis, recurrence, and autopsy demonstrates proof of principle for using these tumours for basic and translational research on paediatric solid tumours. Preclinical models of paediatric solid tumours that could help identify predictive biomarkers of a patient's sensitivity to therapy have been lacking. Over five years, the authors have developed an open access collection of orthotopic xenografts of 12 types of paediatric tumour. Genomic and epigenetic characterization reveals that xenografts retain characteristics of the tumour of origin. A high-throughput drug screen provides a resource for the community to identify potentially efficacious drug combinations. Paediatric solid tumours arise from endodermal, ectodermal, or mesodermal lineages1. Although the overall survival of children with solid tumours is 75%, that of children with recurrent disease is below 30%2. To capture the complexity and diversity of paediatric solid tumours and establish new models of recurrent disease, here we develop a protocol to produce orthotopic patient-derived xenografts at diagnosis, recurrence, and autopsy. Tumour specimens were received from 168 patients, and 67 orthotopic patient-derived xenografts were established for 12 types of cancer. The origins of the patient-derived xenograft tumours were reflected in their gene-expression profiles and epigenomes. Genomic profiling of the tumours, including detailed clonal analysis, was performed to determine whether the clonal population in the xenograft recapitulated the patient’s tumour. We identified several drug vulnerabilities and showed that the combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo.

1 December 2013 in Cancer Cell
Verified
Journal Article
Closed access
XCXiang Chen
Xiang Chen
ESElizabeth Stewart
Elizabeth Stewart
ASAnang A. Shelat
Anang A. Shelat
CQChunxu Qu
Chunxu Qu
Armita BahramiArmita Bahrami
Armita Bahrami
MDMichael A. Dyer
Michael A. Dyer

16 December 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MJMaría Belén Jiménez-Díaz
María Belén Jiménez-Díaz
DEDaniel Ebert
Daniel Ebert
YSYandira Salinas
Yandira Salinas
APAnupam Pradhan
Anupam Pradhan
ALAdele M. Lehane
Adele M. Lehane
RGR. Kiplin Guy
R. Kiplin Guy
Significance: Useful antimalarial drugs must be rapidly acting, highly efficacious, and have low potential for developing resistance. (+)-SJ733 targets a Plasmodium cation-transporting ATPase, ATP4. (+)-SJ733 cleared parasites in vivo as quickly as artesunate by specifically inducing eryptosis/senescence in infected, treated erythrocytes. Although in vitro selection of pfatp4 mutants with (+)-SJ733 proceeded with moderate frequency, during in vivo selection of pbatp4 mutants, resistance emerged slowly and produced marginally resistant mutants with poor fitness. In addition, (+)-SJ733 met all other criteria for a clinical candidate, including high oral bioavailability, a high safety margin, and transmission blocking activity. These results demonstrate that targeting ATP4 has great potential to deliver useful drugs for malaria eradication.

1 November 2014 in Cell Reports
Verified
Journal Article
Open access
ESElizabeth Stewart
Elizabeth Stewart
RGRoss Goshorn
Ross Goshorn
CBCori Bradley
Cori Bradley
LGLyra M. Griffiths
Lyra M. Griffiths
CBClaudia Benavente
Claudia Benavente
MDMichael A. Dyer
Michael A. Dyer
Ewing sarcoma (EWS) is a tumor of the bone and soft tissue that primarily affects adolescents and young adults. With current therapies, 70% of patients with localized disease survive, but patients with metastatic or recurrent disease have a poor outcome. We found that EWS cell lines are defective in DNA break repair and are sensitive to PARP inhibitors (PARPis). PARPi-induced cytotoxicity in EWS cells was 10- to 1,000-fold higher after administration of the DNA-damaging agents irinotecan or temozolomide. We developed an orthotopic EWS mouse model and performed pharmacokinetic and pharmacodynamic studies using three different PARPis that are in clinical development for pediatric cancer. Irinotecan administered on a low-dose, protracted schedule previously optimized for pediatric patients was an effective DNA-damaging agent when combined with PARPis; it was also better tolerated than combinations with temozolomide. Combining PARPis with irinotecan and temozolomide gave complete and durable responses in more than 80% of the mice.

1 May 2017 in Cell Reports
Verified
Journal Article
Open access
Heather SmallwoodHeather Smallwood
Heather Smallwood
SDSusu Duan
Susu Duan
MMMarie Morfouace
Marie Morfouace
SRSvetlana Rezinciuc
Svetlana Rezinciuc
BSBarry L. Shulkin
Barry L. Shulkin
PTPaul G Thomas
Paul G Thomas
Influenza is a worldwide health and financial burden posing a significant risk to the immune-compromised, obese, diabetic, elderly, and pediatric populations. We identified increases in glucose metabolism in the lungs of pediatric patients infected with respiratory pathogens. Using quantitative mass spectrometry, we found metabolic changes occurring after influenza infection in primary human respiratory cells and validated infection-associated increases in c-Myc, glycolysis, and glutaminolysis. We confirmed these findings with a metabolic drug screen that identified the PI3K/mTOR inhibitor BEZ235 as a regulator of infectious virus production. BEZ235 treatment ablated the transient induction of c-Myc, restored PI3K/mTOR pathway homeostasis measured by 4E-BP1 and p85 phosphorylation, and reversed infection-induced changes in metabolism. Importantly, BEZ235 reduced infectious progeny but had no effect on the early stages of viral replication. BEZ235 significantly increased survival in mice, while reducing viral titer. We show metabolic reprogramming of host cells by influenza virus exposes targets for therapeutic intervention.